DE602005008264D1 - Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion - Google Patents

Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion

Info

Publication number
DE602005008264D1
DE602005008264D1 DE602005008264T DE602005008264T DE602005008264D1 DE 602005008264 D1 DE602005008264 D1 DE 602005008264D1 DE 602005008264 T DE602005008264 T DE 602005008264T DE 602005008264 T DE602005008264 T DE 602005008264T DE 602005008264 D1 DE602005008264 D1 DE 602005008264D1
Authority
DE
Germany
Prior art keywords
assisted
patients
sub
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005008264T
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Wei-Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovaxim Ltd
Original Assignee
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd
Publication of DE602005008264D1 publication Critical patent/DE602005008264D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602005008264T 2004-10-04 2005-10-04 Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion Active DE602005008264D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61572904P 2004-10-04 2004-10-04
PCT/IB2005/003384 WO2006038124A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
US11/243,094 US20060093623A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection

Publications (1)

Publication Number Publication Date
DE602005008264D1 true DE602005008264D1 (de) 2008-08-28

Family

ID=35695555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005008264T Active DE602005008264D1 (de) 2004-10-04 2005-10-04 Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion

Country Status (14)

Country Link
US (1) US20060093623A1 (de)
EP (1) EP1797175B1 (de)
JP (1) JP2008515795A (de)
CN (1) CN101056977B (de)
AT (1) ATE401392T1 (de)
AU (1) AU2005290930B2 (de)
BR (1) BRPI0516314A (de)
CA (1) CA2582426A1 (de)
DE (1) DE602005008264D1 (de)
ES (1) ES2310848T3 (de)
IL (1) IL182440A (de)
MX (1) MX2007004028A (de)
RU (1) RU2396346C2 (de)
WO (1) WO2006038124A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213299B1 (de) 2009-01-29 2015-09-09 Michel Vandevelde Impfstoffzusammensetzung auf der Basis eines Virus mit Zinkfingermotiv(en), ihr Herstellungsverfahren und ihre Anwendung
US20100216120A1 (en) * 2009-02-23 2010-08-26 Candace Pert Rapid infectious virus assay
BR112013025481B8 (pt) * 2011-04-06 2022-11-22 Univ Paris Descartes Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos
CN104244975A (zh) * 2012-03-02 2014-12-24 埃斯特韦实验室有限公司 用于制备树突细胞疫苗的方法
EP2821082A1 (de) * 2013-07-05 2015-01-07 Laboratoire Biodim Verfahren zur Herstellung eines inaktivierten Lentivirus, insbesondere HIV, Impfstoff, Kit und Verfahren zur Verwendung
EP3634449A4 (de) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. Alphavirus-neoantigen-vektoren
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
CN114340661A (zh) * 2019-07-02 2022-04-12 磨石生物公司 Hiv抗原和mhc复合物
EP4192496A2 (de) 2020-08-06 2023-06-14 Gritstone bio, Inc. Multiepitop-impfstoffkassetten

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764938B2 (en) * 1998-02-13 2003-09-04 Adan Rios Method for the development of an HIV vaccine
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
AU2001228320A1 (en) * 2000-01-28 2001-08-07 Statens Seruminstitut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
WO2002072140A2 (en) * 2001-02-27 2002-09-19 Institut Pasteur Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
ATE525908T1 (de) * 2002-12-04 2011-10-15 Baylor Res Inst Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
US7611712B2 (en) * 2003-10-23 2009-11-03 Nelson M. Karp Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide

Also Published As

Publication number Publication date
IL182440A (en) 2011-01-31
US20060093623A1 (en) 2006-05-04
RU2007115549A (ru) 2008-11-10
IL182440A0 (en) 2007-07-24
CN101056977B (zh) 2013-01-30
BRPI0516314A (pt) 2008-09-02
RU2396346C2 (ru) 2010-08-10
ATE401392T1 (de) 2008-08-15
MX2007004028A (es) 2007-09-11
AU2005290930A1 (en) 2006-04-13
AU2005290930B2 (en) 2010-12-16
EP1797175A1 (de) 2007-06-20
ES2310848T3 (es) 2009-01-16
CA2582426A1 (en) 2006-04-13
EP1797175B1 (de) 2008-07-16
JP2008515795A (ja) 2008-05-15
CN101056977A (zh) 2007-10-17
WO2006038124A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
EA201490903A1 (ru) Композиции и способы лечения вирусного гепатита c
TW200733953A (en) Materials and methods for treating viral infections
WO2013098655A3 (en) Vaccines directed against human enteroviruses
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
NZ587798A (en) Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
RU2012120671A (ru) Рекомбинантный человеческий белок сс10 для лечения гриппа
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
UA112970C2 (uk) Інактивований вірус вітряної віспи, спосіб його одержання і застосування
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
RU2008130825A (ru) Применение экстракта бузины
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
ATE486088T1 (de) Hiv-impfstoff
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
ATE475426T1 (de) Behandlung oder prävention von hämorrhagischen virusinfektionen mit immunomodulatorischen verbindungen
Caruana Old vaccines can fight new pandemics like COVID-19

Legal Events

Date Code Title Description
8364 No opposition during term of opposition